Fibrosing interstitial lung diseases: knowns and unknowns

V Cottin, L Wollin, A Fischer… - European …, 2019 - Eur Respiratory Soc
Patients with certain types of fibrosing interstitial lung disease (ILD) are at risk of developing
a progressive phenotype characterised by self-sustaining fibrosis, decline in lung function, …

Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis

L Wollin, I Maillet, V Quesniaux, A Holweg… - Journal of Pharmacology …, 2014 - ASPET
The tyrosine kinase inhibitor nintedanib (BIBF 1120) is in clinical development for the treatment
of idiopathic pulmonary fibrosis. To explore its mode of action, nintedanib was tested in …

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis

L Wollin, E Wex, A Pautsch, G Schnapp… - European …, 2015 - Eur Respiratory Soc
Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal disease characterised
by fibrosis of the lung parenchyma and loss of lung function. Although the pathogenic …

Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases

L Wollin, JHW Distler, EF Redente… - European …, 2019 - Eur Respiratory Soc
A proportion of patients with fibrosing interstitial lung diseases (ILDs) develop a progressive
phenotype characterised by decline in lung function, worsening quality of life and early …

In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor

DS Bundschuh, M Eltze, J Barsig, L Wollin… - … of Pharmacology and …, 2001 - ASPET
We have investigated the bronchodilator and anti-inflammatory properties of roflumilast (3-cyclopropylmethoxy-4-difluoromethoxy-N-[3,5-dichloropyrid-4-yl]-benzamide),
a novel, highly …

Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke

…, R Beume, M Lucattelli, L Wollin… - American journal of …, 2005 - atsjournals.org
Rationale: There is a need for new agents capable of suppressing the inflammatory response
in chronic obstructive pulmonary disease. Objectives: This study evaluated the effects of …

Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis

…, K Gelse, O Distler, G Schett, L Wollin… - Annals of the …, 2016 - ard.bmj.com
Background Nintedanib is a tyrosine kinase inhibitor that has recently been shown to slow
disease progression in idiopathic pulmonary fibrosis in two replicate phase III clinical trials. …

Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis

…, CW Chen, O Distler, G Schett, L Wollin… - Annals of the …, 2017 - ard.bmj.com
Background Nintedanib is an inhibitor targeting platelet-derived growth factor receptor,
fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases …

[HTML][HTML] BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis

FE Herrmann, L Wollin, P Nickolaus - Frontiers in Pharmacology, 2022 - frontiersin.org
The anti-inflammatory and immunomodulatory abilities of oral selective phosphodiesterase
4 (PDE4) inhibitors enabled the approval of roflumilast and apremilast for use in chronic …

Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthma

RK Kumar, C Herbert, PS Thomas, L Wollin… - … of Pharmacology and …, 2003 - ASPET
Phosphodiesterase (PDE) inhibitors have potential as alternatives or adjuncts to
glucocorticoid therapy in asthma. We compared roflumilast (a selective PDE4 inhibitor) with …